Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age...
Alekseeva E. I., Dvoryakovskaya T. M., Denisova R., Sleptsova T., Isaeva K., Chomahidze A., Fetisova A., Mamutova A., Alshevskaya A., Gladkikh V., Moskalev A.
Modern Rheumatology
Vol.29, Issue5, P. 848-855
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1080/14397595.2018.1516329
Аннотация:
Objective: The aim of this study was to analyze the efficacy and safety of etanercept (ETA) in children with juvenile idiopathic arthritis (JIA) under the age of 4 years and to compare the data with those for older age groups. Methods: Three groups comprising 34 patients each (total of 102 patients) were selected using the propensity score matching (PSM) method. The study group (patients under the age of 4 years; the Junior group (JNR)) was compared with patients of the older age groups, adjusted for criteria such as gender, JIA category, JIA severity, and either age at disease onset (the Reference by Age of disease Onset (RAO) group) or disease duration (the Reference by Disease Duration (RDD) group). Results: All three groups showed a good response to ETA therapy. During the follow-up period, only 4 (3.9[%]) patients failed to reach American College of Rheumatology (ACR) Pediatric criteria improvement at ACR50 level. In the JNR group, 82.4[%] of patients achieved ACR90 within a median ti
Ключевые слова:
etanercept; juvenile idiopathic arthritis; propensity score
abatacept; C reactive protein; etanercept; antirheumatic agent; etanercept; Article; child; clinical article; cohort analysis; comparative study; disease activity score; disease duration; disease exacerbation; disease severity; drug efficacy; drug response; drug safety; drug substitution; drug tolerability; drug withdrawal; erythrocyte sedimentation rate; female; follow up; herpes zoster; human; injection site reaction; juvenile rheumatoid arthritis; liver toxicity; male; morning stiffness; preschool child; priority journal; propensity score; relapse; remission; respiratory tract infection; uveitis; visual analog scale; adolescent; age; aged; juvenile rheumatoid arthritis; propensity score; Adolescent; Age Factors; Aged; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Etanercept; Female; Humans; Male; Propensity Score
Язык текста: Английский
ISSN: 1439-7609
Alekseeva E. I. Ekaterina Iosifovna 1962-
Dvoryakovskaya T. M. Tat`yana Maratovna 1975-
Denisova R.
Sleptsova T.
Isaeva K.
Chomahidze A.
Fetisova A.
Mamutova A.
Alshevskaya A.
Gladkikh V.
Moskalev A.
Алексеева Е. И. Екатерина Иосифовна 1962-
Дворяковская Т. М. Татьяна Маратовна 1975-
Денисова Р.
Слепцова Т.
Исаева К.
Чомахидзе А.
Фетисова А.
Мамутова А.
Алшевскайа А.
Гладких В.
Москалев А.
Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method
Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age...
Текст визуальный непосредственный
Modern Rheumatology
Springer-Verlag Tokyo Inc.
Vol.29, Issue5 P. 848-855
2019
Статья
etanercept juvenile idiopathic arthritis propensity score
abatacept C reactive protein etanercept antirheumatic agent etanercept Article child clinical article cohort analysis comparative study disease activity score disease duration disease exacerbation disease severity drug efficacy drug response drug safety drug substitution drug tolerability drug withdrawal erythrocyte sedimentation rate female follow up herpes zoster human injection site reaction juvenile rheumatoid arthritis liver toxicity male morning stiffness preschool child priority journal propensity score relapse remission respiratory tract infection uveitis visual analog scale adolescent age aged juvenile rheumatoid arthritis propensity score Adolescent Age Factors Aged Antirheumatic Agents Arthritis, Juvenile Child Child, Preschool Etanercept Female Humans Male Propensity Score
Objective: The aim of this study was to analyze the efficacy and safety of etanercept (ETA) in children with juvenile idiopathic arthritis (JIA) under the age of 4 years and to compare the data with those for older age groups. Methods: Three groups comprising 34 patients each (total of 102 patients) were selected using the propensity score matching (PSM) method. The study group (patients under the age of 4 years; the Junior group (JNR)) was compared with patients of the older age groups, adjusted for criteria such as gender, JIA category, JIA severity, and either age at disease onset (the Reference by Age of disease Onset (RAO) group) or disease duration (the Reference by Disease Duration (RDD) group). Results: All three groups showed a good response to ETA therapy. During the follow-up period, only 4 (3.9[%]) patients failed to reach American College of Rheumatology (ACR) Pediatric criteria improvement at ACR50 level. In the JNR group, 82.4[%] of patients achieved ACR90 within a median ti